Insider sales post-merger announcement are common and not necessarily bearish, but monitor any unusual patterns or changes in deal sentiment. The merger agreement appears to be the main catalyst; focus on stockholder vote and regulatory clearances.
APGE drugs
APGE drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Jun 25 $132.68entry
- T+1 · 5mo ago −0.10%α +0.63% · $132.55
- T+5 · 5mo ago +0.07%α −1.49% · $132.77
- T+20 · 4mo ago +1.19%α +0.66% · $134.26
- T+60 · due 8w ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two top insiders (CEO and CMO) sold a total of $14.1M in open-market transactions on June 22, 2026, just days after the company announced a merger agreement with AbbVie. The sales represent 0.14% of market cap and are likely routine monetization ahead of the deal close, but the timing draws attention.
Key Financial Metrics
Key Facts
- CEO Michael Thomas Henderson sold 80,000 shares at $132.54 (~$10.6M) on June 22.
- CMO Carl Dambkowski sold 26,400 shares at $132.60 (~$3.5M) on June 22.
- Total insider sales of $14.1M represent 0.14% of APGE's $10B market cap.
- Sales occurred 4 days after the June 18 merger agreement with AbbVie (via Andor entities).
Financial Impact
$14.1M in insider sales, representing 0.14% of market cap
Risk Factors
- Additional insider sales could erode confidence in deal completion.
- Regulatory or stockholder approval delays could affect timeline.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-APGE-1782345739974 |
Track record
31 reports on APGE
9 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +73.31% at T+60 after the May 27, 2026 report. 12 of 13 went positive at some point.
Filters
- Sep 14, 20269w ago 15-12G Neutral 4/10 No price data
- Sep 3, 202610w ago 25-NSE Bullish 8/10 Entry $135.06 No price data
- Sep 3, 202610w ago 8-K Bullish 8/10 Entry $135.06 No price data
- Aug 11, 202613w ago 8-K Bullish 7/10 Entry $134.55 No price data
- Aug 10, 202614w ago 8-K Bullish 8/10 No price data
- Aug 10, 202614w ago Press Release Bullish 8/10 Entry $134.65 No price data
- Aug 6, 202614w ago Institutional Cluster Mixed 5/10 Entry $134.49 to $135.07 ▲ +0.43% −0.17% vs SPY
- Aug 3, 202615w ago DEFA14A Bullish 5/10 Entry $134.19 to $135.08 ▲ +0.66% +1.90% vs SPY
- Jul 10, 202618w ago Insider Cluster Neutral 2/10 Entry $133.82 to $134.65 ▲ +0.62% −2.56% vs SPY
- Jun 26, 202620w ago DEFA14A Bullish 6/10 Entry $132.61 to $134.28 ▲ +1.26% +1.54% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers